U.S. markets close in 5 hours 34 minutes
  • S&P 500

    3,452.25
    +25.33 (+0.74%)
     
  • Dow 30

    28,391.37
    +195.95 (+0.69%)
     
  • Nasdaq

    11,556.18
    +77.30 (+0.67%)
     
  • Russell 2000

    1,629.86
    +16.24 (+1.01%)
     
  • Crude Oil

    40.68
    -0.15 (-0.37%)
     
  • Gold

    1,904.00
    -7.70 (-0.40%)
     
  • Silver

    24.76
    +0.07 (+0.27%)
     
  • EUR/USD

    1.1839
    +0.0066 (+0.56%)
     
  • 10-Yr Bond

    0.7940
    +0.0330 (+4.34%)
     
  • GBP/USD

    1.2967
    +0.0026 (+0.20%)
     
  • USD/JPY

    105.5890
    +0.1590 (+0.15%)
     
  • BTC-USD

    11,931.74
    +874.73 (+7.91%)
     
  • CMC Crypto 200

    240.09
    +1.17 (+0.49%)
     
  • FTSE 100

    5,911.95
    +27.30 (+0.46%)
     
  • Nikkei 225

    23,567.04
    -104.09 (-0.44%)
     

Beigene (BGNE) CFO & Chief Strategy Officer Howard Liang Sold $4.2 million of Shares

GuruFocus.com
·2 mins read

- By insider

CFO & Chief Strategy Officer of Beigene (30-Year Financial, Insider Trades) Howard Liang (insider trades) sold 14,000 shares of BGNE on 10/05/2020 at an average price of $299.6 a share. The total sale was $4.2 million.


BeiGene Ltd is a biopharmaceutical company engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. Its product includes BGB-3111, BGB-A317 and BGB-290 and one immuno-oncology agent. BeiGene Ltd has a market cap of $28.05 billion; its shares were traded at around $297.55 with and P/S ratio of 91.20. GuruFocus has detected 5 severe warning signs with BeiGene Ltd. .

CEO Recent Trades:

  • CEO John Oyler sold 54,303 shares of BGNE stock on 09/29/2020 at the average price of $280.39. The price of the stock has increased by 6.12% since.

  • CEO John Oyler sold 81,228 shares of BGNE stock on 09/16/2020 at the average price of $253.46. The price of the stock has increased by 17.4% since.

CFO Recent Trades:

  • CFO & Chief Strategy Officer Howard Liang sold 14,000 shares of BGNE stock on 10/05/2020 at the average price of $299.6. The price of the stock has decreased by 0.68% since.

  • CFO & Chief Strategy Officer Howard Liang sold 14,000 shares of BGNE stock on 09/14/2020 at the average price of $250.27. The price of the stock has increased by 18.89% since.

Directors and Officers Recent Trades:

  • Chair, Scientific Advisory Brd Xiaodong Wang sold 5,000 shares of BGNE stock on 10/05/2020 at the average price of $300. The price of the stock has decreased by 0.82% since.

  • President & GM China Xiaobin Wu sold 4,000 shares of BGNE stock on 10/05/2020 at the average price of $300. The price of the stock has decreased by 0.82% since.

  • CMO, Hematology Jane Huang sold 1,500 shares of BGNE stock on 09/29/2020 at the average price of $280.38. The price of the stock has increased by 6.12% since.

  • Chair, Scientific Advisory Brd Xiaodong Wang sold 5,000 shares of BGNE stock on 09/25/2020 at the average price of $280.42. The price of the stock has increased by 6.11% since.

  • President & GM China Xiaobin Wu sold 4,000 shares of BGNE stock on 09/25/2020 at the average price of $280.35. The price of the stock has increased by 6.14% since.

For the complete insider trading history of BGNE, click here

.This article first appeared on GuruFocus.